ETCHX: Eventide Healthcare & Life Sciences C

Welcome to MutualFunds.com. Please help us personalize your experience.

Select the one that best describes you

Your personalized experience is almost ready.

Join other Individual Investors receiving FREE personalized market updates and research. Join other Institutional Investors receiving FREE personalized market updates and research. Join other Financial Advisors receiving FREE personalized market updates and research.

Thank you!

Check your email and confirm your subscription to complete your personalized experience.

Thank you for your submission, we hope you enjoy your experience

Channels

Find the latest content and information here about the 2019 Charles Schwab Impact Conference.

Advisors

Receive email updates about fund flows, news, upcoming CE accredited webcasts from industry thought leaders and more.

Content focused on helping financial advisors build successful client relationships and grow their business.

Content geared towards helping financial advisors build better client portfolios.

Get insights on the industry trends and investment news from leading fund managers and experts.

ETCHX Eventide Healthcare & Life Sciences C

  • Fund
  • ETCHX
  • Price as of: Dec 12, 2019
  • $37.29
    + $0.70 + 1.91%

Profile

ETCHX - Profile

Vitals

  • YTD Return 47.7%
  • 3 Yr Annualized Return 23.8%
  • 5 Yr Annualized Return 13.4%
  • Net Assets $1.16 B
  • Holdings in Top 10 42.6%

52 WEEK LOW AND HIGH

$37.29
$22.91
$37.29

Expenses

OPERATING RELATED FEES

  • Expense Ratio 2.29%

SALES FEES

  • Front Load N/A
  • Deferred Load 1.00%

BROKERAGE FEES

  • Turnover 53.00%

TRADING FEES

  • Max Redemption Fee 1.00%

Min Investment

  • Standard (Taxable) $1,000
  • IRA $1,000

Fund Classification


Distributions

  • YTD Total Return 47.7%
  • 3 Yr Annualized Total Return 24.4%
  • 5 Yr Annualized Total Return 14.0%
  • Capital Gain Distribution Frequency Annually
  • Net Income Ratio -2.18%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name
    Eventide Healthcare & Life Sciences Fund
  • Fund Family Name
    Eventide Funds
  • Inception Date
    Dec 27, 2012
  • Shares Outstanding
    N/A
  • Share Class
    C
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    Finny Kuruvilla

Fund Description

Under normal market conditions, the fund will invest at least 80% of its net assets (plus borrowings for investment purposes) in equity and equity-related securities of companies in the healthcare and life sciences sectors, including common stock, options, preferred stock and convertible debt. It may invest without limitation in securities of companies domiciled outside the United States either directly or through American Depositary Receipts ("ADRs"). The fund may invest in securities of companies of any market capitalization.


Get Updates About ETCHX

Sign up for Advisor Access to receive email updates about ETCHX competitors, news, CE accredited webcasts and more.

Please Enter Your Email
Please Select Your Advisor Type

Categories

Performance

ETCHX - Performance

Return Ranking - Trailing

Period ETCHX Return Category Return Low Category Return High Rank in Category (%)
YTD 47.7% 3.4% 49.1% 3.42%
1 Yr 27.4% -12.6% 29.3% 3.42%
3 Yr 23.8%* -14.0% 28.3% 6.42%
5 Yr 13.4%* -11.5% 15.4% 4.81%
10 Yr N/A* -1.8% 16.8% N/A

* Annualized

Return Ranking - Calendar

Period ETCHX Return Category Return Low Category Return High Rank in Category (%)
2018 -8.2% -25.3% 21.5% 60.36%
2017 42.4% -10.8% 43.9% 3.67%
2016 -16.9% -31.6% 6.9% 58.49%
2015 12.6% -20.4% 13.8% 3.88%
2014 28.1% -5.8% 31.5% 12.50%

Total Return Ranking - Trailing

Period ETCHX Return Category Return Low Category Return High Rank in Category (%)
YTD 47.7% 3.4% 49.1% 3.42%
1 Yr 27.4% -12.6% 38.1% 3.42%
3 Yr 24.4%* -14.0% 28.5% 5.50%
5 Yr 14.0%* -11.5% 17.0% 5.77%
10 Yr N/A* -1.8% 18.0% N/A

* Annualized

Total Return Ranking - Calendar

Period ETCHX Return Category Return Low Category Return High Rank in Category (%)
2018 -8.2% -25.3% 22.2% 63.96%
2017 44.4% -10.8% 45.8% 3.67%
2016 -16.9% -26.4% 8.7% 71.70%
2015 14.0% -16.6% 15.2% 3.88%
2014 28.1% -5.8% 36.7% 27.08%

NAV & Total Return History


Holdings

ETCHX - Holdings

Concentration Analysis

ETCHX Category Low Category High ETCHX % Rank
Net Assets 1.16 B 3.25 M 47.5 B 49.61%
Number of Holdings 53 26 388 84.25%
Net Assets in Top 10 379 M 913 K 17.4 B 59.84%
Weighting of Top 10 42.62% 21.3% 77.1% 37.80%

Top 10 Holdings

  1. Ascendis Pharma A/S ADR 6.24%
  2. Sage Therapeutics Inc 5.68%
  3. Biohaven Pharmaceutical Holding Co Ltd 4.85%
  4. Zogenix Inc 4.58%
  5. Sarepta Therapeutics Inc 4.23%
  6. Blueprint Medicines Corp 3.82%
  7. MyoKardia Inc 3.64%
  8. Neurocrine Biosciences Inc 3.58%
  9. Aimmune Therapeutics Inc 3.02%
  10. Galapagos NV ADR 2.97%

Asset Allocation

Weighting Return Low Return High ETCHX % Rank
Stocks
93.77% 90.21% 103.54% 96.06%
Other
5.17% -27.41% 5.17% 1.57%
Cash
1.06% 0.00% 9.79% 53.54%
Preferred Stocks
0.00% 0.00% 1.08% 22.05%
Convertible Bonds
0.00% 0.00% 1.54% 16.54%
Bonds
0.00% 0.00% 20.60% 15.75%

Stock Sector Breakdown

Weighting Return Low Return High ETCHX % Rank
Healthcare
91.96% 56.22% 99.75% 88.98%
Industrials
1.81% 0.00% 2.40% 3.15%
Utilities
0.00% 0.00% 0.00% 7.87%
Technology
0.00% 0.00% 16.35% 39.37%
Real Estate
0.00% 0.00% 5.81% 16.54%
Financial Services
0.00% 0.00% 5.93% 28.35%
Energy
0.00% 0.00% 0.43% 11.81%
Communication Services
0.00% 0.00% 1.02% 11.81%
Consumer Defense
0.00% 0.00% 34.83% 17.32%
Consumer Cyclical
0.00% 0.00% 10.49% 16.54%
Basic Materials
0.00% 0.00% 1.94% 33.07%

Stock Geographic Breakdown

Weighting Return Low Return High ETCHX % Rank
US
81.92% 58.61% 99.93% 48.03%
Non US
11.85% 0.00% 40.52% 65.35%

Expenses

ETCHX - Expenses

Operational Fees

ETCHX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 2.29% 0.10% 4.94% 9.40%
Management Fee 1.10% 0.09% 1.30% 90.55%
12b-1 Fee 1.00% 0.00% 1.00% 70.83%
Administrative Fee 0.10% 0.01% 0.40% 35.71%

Sales Fees

ETCHX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 2.50% 5.75% N/A
Deferred Load 1.00% 1.00% 5.00% 20.83%

Trading Fees

ETCHX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee 1.00% 0.75% 2.00% 46.34%

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

ETCHX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 53.00% 0.00% 341.00% 72.88%

Distributions

ETCHX - Distributions

Dividend Yield Analysis

ETCHX Category Low Category High ETCHX % Rank
Dividend Yield 0.00% 0.00% 5.43% 22.83%

Dividend Distribution Analysis

ETCHX Category Low Category High Category Mod
Dividend Distribution Frequency Annually Annually Quarterly Annually

Net Income Ratio Analysis

ETCHX Category Low Category High ETCHX % Rank
Net Income Ratio -2.18% -2.24% 2.12% 99.15%

Capital Gain Distribution Analysis

ETCHX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Annually Semi-Annually Annually

Dividend Payout History

View More +

Fund Manager Analysis

ETCHX - Fund Manager Analysis

Managers

Finny Kuruvilla


Start Date

Tenure

Tenure Rank

Dec 27, 2012

6.93

6.9%

Finny Kuruvilla, M.D., Ph.D., has been primarily responsible for the day-to-day management of the Gilead Fund and Healthcare & Life Sciences Fund since inception. Dr. Kuruvilla has been the Managing Partner of the Adviser since its inception in 2008. Dr. Kuruvilla possesses a diverse background in quantitative methods, with applications focused on innovations in science, engineering, and medicine. He holds an MD from Harvard Medical School, a PhD in Chemistry and Chemical Biology from Harvard University, a master’s degree in Electrical Engineering and Computer Science from MIT, and a bachelor’s degree from Caltech in Chemistry. From 2005-2008, Dr. Kuruvilla was a clinical fellow at the Brigham and Women's Hospital and a postdoctoral scientist at MIT. As an avid proponent of values-based investing, Dr. Kuruvilla has established rigorous standards in seeking out the most ethical companies at the outset of the stock selection process. In addition to his role with the Adviser, Dr. Kuruvilla is a founder, financial sponsor, and Board Director of Sattler College, a four-year college in Boston, Massachusetts, opened in 2018. Dr. Kuruvilla also contributes to the college in a limited faculty role. From 2008-2016, Dr. Kuruvilla provided research services as an employee of Clarus Ventures, a healthcare and life sciences venture capital firm. From 2006-2008, Dr. Kuruvilla was a research fellow at the Broad Institute of Harvard and MIT.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.34 22.22 9.78 19.59